Abstract
Purpose of Review: While most patients with chronic myeloid leukemia (CML) present in a chronic phase and are expected to have a normal life expectancy, some patients present with or progress to a more aggressive accelerated phase (AP) or blast phase (BP) of CML. Herein, we discuss the diagnostic considerations of advanced phase CML and review its contemporary management. Recent Findings: Later-generation, more potent BCR::ABL1 tyrosine kinase inhibitors (TKIs) such as ponatinib may result in superior outcomes in patients with advanced phase CML. For CML-BP, combination approaches directed against the blast immunophenotype appear superior to TKI monotherapy. The role of allogeneic stem cell transplantation is controversial in CML-AP but has consistently been shown to improve outcomes for patients with CML-BP. Summary: Advanced phase CML, particularly CML-BP, remains a poor risk subtype of CML. However, novel combination approaches using later-generation TKIs are being explored in clinical trials and may lead to improved outcomes.
Original language | English (US) |
---|---|
Pages (from-to) | 234-242 |
Number of pages | 9 |
Journal | Current hematologic malignancy reports |
Volume | 18 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2023 |
Keywords
- Accelerated phase CML
- BCR::ABL1
- Blast phase CML
- Chronic myeloid leukemia
- Philadelphia chromosome
- Ponatinib
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research